Relief Therapeutics Holding AG
0QKQ.L
0QKQ.LRelief Therapeutics Holding AG
London Stock Exchange2.19
CHF
-0.20
(-8.37%)
ISIN
CH1251125998
Return %
Stock
S&P500
1Y
97.30
9.50
3Y
-79.02
58.73
5Y
-98.27
91.32
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mr. Jeremy Meinen CPA
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Bâtiment F2/F3 Geneva Switzerland 1202
- IPO Date
- Jan 18, 2021
- Website
- relieftherapeutics.com
- Similar Companies
- Business
- Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.